×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AcelRx becomes Talphera, adopting new name to reflect pain pivot
Fierce Pharma
AcelRx becomes Talphera, adopting new name to reflect pain pivot ... AcelRx Pharmaceuticals wants to put a tough few years behind it. After...
3 months ago
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PR Newswire
Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational...
5 months ago
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
Yahoo Finance
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization...
7 months ago
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
PR Newswire
PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and...
3 months ago
AcelRx Pharma (ACRX) to Rebrand as Talphera, Inc
StreetInsider
AcelRx Pharma (ACRX) to Rebrand as Talphera, Inc ... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the rebranding of the Company,...
3 months ago
Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc
Yahoo Finance
On September 11, 2023, Vincent Angotti, the CEO of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), made a significant insider purchase of 10000...
7 months ago
Insider Buying: CEO Vincent Angotti Acquires 10000 Shares of AcelRx Pharmaceuticals Inc
GuruFocus
On September 11, 2023, Vincent Angotti, the CEO of AcelRx Pharmaceuticals Inc (ACRX), made a significant insider purchase of 10000 shares of...
7 months ago
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal ...
PR Newswire
AcelRx's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational...
4 months ago
AcelRx Pharma (ACRX) Receives Nasdaq Non-compliance Notice
StreetInsider
To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of ten consecutive...
6 months ago
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Is Expected To Breakeven In The Near Future
Yahoo Movies UK
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company.
2 weeks ago